Whether that makes CTCs a good biosource to screen for PD-L1 and how levels of PD-L1 on melanoma CTCs, measureable with this relatively fast and easy detection assay, correlate to patient response needs to be investigated in larger scale studies. The gene discussed is CD274; the disease is melanoma.